Balyasny Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Balyasny Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-91,200	Closed	-$6.98M	–	2895
2025 Q4	$6.98M	Sell	91,200 -12,300	-12%	-$807K	0.01%	1215
2025 Q3	$5.38M	Buy	103,500 +14,300	+16%	+$697K	0.01%	1344
2025 Q2	$3.85M	Buy	89,200 +69,800	+360%	+$2.54M	0.01%	1409
2025 Q1	$671K	Buy	+19,400	New	+$654K	﹤0.01%	2169
2024 Q4	–	Sell	-69,900	Closed	-$1.78M	–	2735
2024 Q3	$1.78M	Buy	+69,900	New	+$1.84M	﹤0.01%	1723
2022 Q4	–	Sell	-25,000	Closed	-$249K	–	2777
2022 Q3	$249K	Buy	+25,000	New	+$260K	﹤0.01%	2253
2022 Q1	–	Sell	-48,700	Closed	-$812K	–	2471
2021 Q4	$812K	Buy	+48,700	New	+$2.06M	﹤0.01%	1500
2021 Q1	–	Sell	-50,000	Closed	-$3.56M	–	1756
2020 Q4	$3.56M	Buy	+50,000	New	+$2.41M	0.02%	747

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's BBIO Position: Q1 2026 in Review

Balyasny Asset Management increased its BridgeBio Pharma (BBIO) stake by 49% in Q1 2026, buying an estimated $8.39M and bringing the position to 350,096 shares worth $26M. The position accounts for 0.03% of the portfolio, ranked #586.

Balyasny Asset Management first reported a position in BBIO in Q1 2022 and has held it in 9 quarters since. The position peaked at $70.9M in Q2 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Balyasny Asset Management held 350,096 shares of BridgeBio Pharma worth $26M as of Q1 2026.
Balyasny Asset Management bought 115,707 BridgeBio Pharma shares in Q1 2026, an estimated $8.39M.
BridgeBio Pharma made up 0.03% of Balyasny Asset Management's portfolio in Q1 2026, its #586 holding.
Balyasny Asset Management first reported a position in BridgeBio Pharma in Q1 2022 and has held it in 9 quarters since.
Balyasny Asset Management's BridgeBio Pharma position peaked at $70.9M in Q2 2025.
458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.